Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials is a research paper published in Journal of Cystic Fibrosis (2023). On theSindex it has a DataRank of 0.347. It has been cited 5 times, with 4 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.269
From this paper's citation signal
Citation Network Contribution
0.0786
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 4 citers.
NCATS NIH HHS
Grant: UL1 TR002548
Cystic Fibrosis Foundation
Grant: ZEMANI17Y5
National Institutes of Health
Grant: P30 DK 089507
Cystic Fibrosis Foundation
Grant: ZEMANI17K0
National Institutes of Health
Grant: P01HL128192
NCATS NIH HHS
Grant: UL1 TR002319
Cystic Fibrosis Foundation
Grant: HAMBLE17K0
Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg
FWCI
0.83
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords